The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how gut microbial dysbiosis relates to the efficacy and safety of immunochemotherapy in diffuse large B-cell lymphoma (DLBCL). Researchers collected stool from treatment-naive, newly diagnosed patients. They performed 16S ribosomal RNA gene sequencing and whole-genome shotgun sequencing. Microbiome features were compared with healthy controls. The team then tested whether microbiome characteristics were associated with treatment outcomes, febrile neutropenia, relapse, and cytokine profiles.
Who was studied?
The cohort was 189 treatment-naive patients with newly diagnosed DLBCL. Stool from 158 patients underwent 16S sequencing, and an additional 106 samples underwent whole-genome shotgun sequencing. Patient microbiome data were compared with data from healthy controls. This was a human clinical study, not an animal or in-vitro model. The study population and control comparisons were used to link microbial features to immunochemotherapy efficacy and safety.
What were the most important findings?
Alpha diversity was significantly lower in DLBCL patients than in healthy controls (p less than .001), and overall composition differed significantly (p less than .001). Enterobacteriaceae, a family within Proteobacteria, was markedly enriched in patients. Functional analysis linked this to opportunistic traits: type 1 pili, biofilm formation, and antibiotic resistance. Enterobacteriaceae were enriched in patients with febrile neutropenia and in those who relapsed or progressed (p less than .001). Greater Enterobacteriaceae abundance correlated with shorter progression-free survival (p 0.007) and with interleukin 6 (p 0.035) and interferon gamma (p 0.045) levels.
What are the greatest implications of this study?
The findings show DLBCL patients carry gut dysbiosis marked by Enterobacteriaceae enrichment, which tracks with worse outcomes and treatment toxicity. This suggests the gut microbiome could inform risk assessment in lymphoma. The associations are correlational, and the authors note that the origin and role of dysbiosis remain unresolved. Enterobacteriaceae enrichment may be a marker rather than a driver of poor outcomes. Further study is needed to clarify causation and to test whether modifying the microbiome improves immunochemotherapy safety or efficacy.